J.W. Cole Advisors Inc. Acquires 1,354 Shares of Gilead Sciences, Inc. $GILD

J.W. Cole Advisors Inc. grew its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 6.2% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 23,081 shares of the biopharmaceutical company’s stock after acquiring an additional 1,354 shares during the period. J.W. Cole Advisors Inc.’s holdings in Gilead Sciences were worth $2,559,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in GILD. Vanguard Group Inc. lifted its holdings in Gilead Sciences by 1.6% during the 2nd quarter. Vanguard Group Inc. now owns 119,364,226 shares of the biopharmaceutical company’s stock worth $13,233,912,000 after purchasing an additional 1,893,401 shares in the last quarter. Geode Capital Management LLC grew its holdings in Gilead Sciences by 2.6% during the 2nd quarter. Geode Capital Management LLC now owns 29,207,662 shares of the biopharmaceutical company’s stock valued at $3,231,548,000 after buying an additional 727,515 shares in the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of Gilead Sciences by 314.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company’s stock valued at $1,647,484,000 after buying an additional 11,156,382 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Gilead Sciences by 12.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 13,755,481 shares of the biopharmaceutical company’s stock worth $1,541,302,000 after buying an additional 1,520,809 shares in the last quarter. Finally, Nuveen LLC bought a new position in shares of Gilead Sciences in the first quarter valued at approximately $620,415,000. 83.67% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on GILD. BMO Capital Markets set a $135.00 target price on shares of Gilead Sciences in a report on Tuesday. Scotiabank assumed coverage on shares of Gilead Sciences in a report on Thursday, November 13th. They issued a “sector outperform” rating and a $140.00 price target on the stock. Weiss Ratings reissued a “buy (b)” rating on shares of Gilead Sciences in a research note on Wednesday, October 8th. Wells Fargo & Company boosted their target price on Gilead Sciences from $140.00 to $145.00 and gave the stock an “overweight” rating in a research report on Friday, October 31st. Finally, Wall Street Zen raised Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 15th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $130.65.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $125.23, for a total transaction of $313,075.00. Following the completion of the sale, the chief financial officer directly owned 154,555 shares in the company, valued at $19,354,922.65. This represents a 1.59% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Daniel Patrick O’day sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, October 28th. The shares were sold at an average price of $119.39, for a total value of $1,193,900.00. Following the transaction, the chief executive officer directly owned 581,203 shares in the company, valued at $69,389,826.17. This trade represents a 1.69% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 115,146 shares of company stock valued at $14,012,141. Insiders own 0.27% of the company’s stock.

Gilead Sciences Trading Up 0.3%

NASDAQ GILD opened at $127.51 on Friday. The stock’s 50-day simple moving average is $119.64 and its two-hundred day simple moving average is $114.34. Gilead Sciences, Inc. has a twelve month low of $88.57 and a twelve month high of $128.70. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13. The company has a market capitalization of $158.20 billion, a price-to-earnings ratio of 25.40, a PEG ratio of 0.81 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, beating the consensus estimate of $2.16 by $0.31. The firm had revenue of $7.77 billion for the quarter, compared to analyst estimates of $7.42 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The company’s revenue was up 3.0% on a year-over-year basis. During the same period in the prior year, the company earned $2.02 EPS. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Research analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th will be paid a dividend of $0.79 per share. The ex-dividend date of this dividend is Monday, December 15th. This represents a $3.16 annualized dividend and a dividend yield of 2.5%. Gilead Sciences’s dividend payout ratio (DPR) is 48.99%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.